S. -. Lee

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a phase 1/2, randomized, placebo-controlled, observer-blinded trial

Y. K. Kim, A. Walls, D. Veesler, 2022, medRxiv.